Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye drops

Abstract This study assessed the clinical risk factors for periorbital dermatitis (PD) after using dorzolamide/timolol eye drops in a total of 1282 glaucoma patients. Both the PD(+) group and the PD(−) group were evaluated using clinical data such as age, sex, dosing duration, presence of benzalkoni...

Full description

Bibliographic Details
Main Authors: Myungjin Kim, Hyoju Jang, Seungsoo Rho
Format: Article
Language:English
Published: Nature Portfolio 2021-09-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-97565-0
_version_ 1818852016278994944
author Myungjin Kim
Hyoju Jang
Seungsoo Rho
author_facet Myungjin Kim
Hyoju Jang
Seungsoo Rho
author_sort Myungjin Kim
collection DOAJ
description Abstract This study assessed the clinical risk factors for periorbital dermatitis (PD) after using dorzolamide/timolol eye drops in a total of 1282 glaucoma patients. Both the PD(+) group and the PD(−) group were evaluated using clinical data such as age, sex, dosing duration, presence of benzalkonium chloride (BAK) in the formulation, ocular surgery history (e.g. cataract or glaucoma operations), height, weight, personal history of systemic hypertension, smoking, alcohol consumption, intraocular pressure, best-corrected visual acuity (BCVA), central corneal thickness, axial length, and visual field index (VFI). Univariate analyses showed that shorter dosing duration, higher rate of BAK-included cases, worse BCVA, worse VFI, more systemic hypertension history, and more ocular surgery history were more associated with the PD(+) group than the PD(−) group. The BAK(−) group showed a lower PD rate than the BAK-included group, which was supported by the Kaplan–Meier analysis (log-rank test, p = 0.0014). Multivariate analyses revealed that the probability of PD increased by 8 times if they had a history of ocular surgery and increased by 2.3% when the VFI decreased by 1% (Cox’s hazard regression test, p < 0.001). Therefore, a preservative-free dorzolamide/timolol can benefit the subjects for those who had ocular surgery or who have worse VFI.
first_indexed 2024-12-19T07:14:13Z
format Article
id doaj.art-e3f88d173aec4c2baf3a503b9d1d7a25
institution Directory Open Access Journal
issn 2045-2322
language English
last_indexed 2024-12-19T07:14:13Z
publishDate 2021-09-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj.art-e3f88d173aec4c2baf3a503b9d1d7a252022-12-21T20:31:07ZengNature PortfolioScientific Reports2045-23222021-09-011111710.1038/s41598-021-97565-0Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye dropsMyungjin Kim0Hyoju Jang1Seungsoo Rho2Department of Ophthalmology, CHA Bundang Medical Center, CHA UniversitySW Bright Eye ClinicDepartment of Ophthalmology, CHA Bundang Medical Center, CHA UniversityAbstract This study assessed the clinical risk factors for periorbital dermatitis (PD) after using dorzolamide/timolol eye drops in a total of 1282 glaucoma patients. Both the PD(+) group and the PD(−) group were evaluated using clinical data such as age, sex, dosing duration, presence of benzalkonium chloride (BAK) in the formulation, ocular surgery history (e.g. cataract or glaucoma operations), height, weight, personal history of systemic hypertension, smoking, alcohol consumption, intraocular pressure, best-corrected visual acuity (BCVA), central corneal thickness, axial length, and visual field index (VFI). Univariate analyses showed that shorter dosing duration, higher rate of BAK-included cases, worse BCVA, worse VFI, more systemic hypertension history, and more ocular surgery history were more associated with the PD(+) group than the PD(−) group. The BAK(−) group showed a lower PD rate than the BAK-included group, which was supported by the Kaplan–Meier analysis (log-rank test, p = 0.0014). Multivariate analyses revealed that the probability of PD increased by 8 times if they had a history of ocular surgery and increased by 2.3% when the VFI decreased by 1% (Cox’s hazard regression test, p < 0.001). Therefore, a preservative-free dorzolamide/timolol can benefit the subjects for those who had ocular surgery or who have worse VFI.https://doi.org/10.1038/s41598-021-97565-0
spellingShingle Myungjin Kim
Hyoju Jang
Seungsoo Rho
Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye drops
Scientific Reports
title Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye drops
title_full Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye drops
title_fullStr Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye drops
title_full_unstemmed Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye drops
title_short Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye drops
title_sort risk factors for periorbital dermatitis in patients using dorzolamide timolol eye drops
url https://doi.org/10.1038/s41598-021-97565-0
work_keys_str_mv AT myungjinkim riskfactorsforperiorbitaldermatitisinpatientsusingdorzolamidetimololeyedrops
AT hyojujang riskfactorsforperiorbitaldermatitisinpatientsusingdorzolamidetimololeyedrops
AT seungsoorho riskfactorsforperiorbitaldermatitisinpatientsusingdorzolamidetimololeyedrops